Mar 1 |
Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice
|
Mar 1 |
Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade
|
Mar 1 |
Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why
|
Mar 1 |
Protagonist Therapeutics Full Year 2023 Earnings: Beats Expectations
|
Feb 29 |
We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn
|
Feb 28 |
Protagonist GAAP EPS of $0.44
|
Feb 27 |
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Feb 25 |
Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
|
Feb 21 |
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
|
Feb 15 |
Steven Cohen Adjusts Position in Protagonist Therapeutics Inc
|